A neuropharmacologic approach to self-mutilating behavior.
D000818:Animals; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003864:Depression, Chemical; D004298:Dopamine; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009388:Neostigmine / Q000627:therapeutic use; D009966:Orphenadrine / Q000009:adverse effects*; D051381:Rats; D011955:Receptors, Drug; D012652:Self Mutilation / Q000139:chemically induced / Q000517:prevention & control*
D002800:Cholinesterase Inhibitors; D011955:Receptors, Drug; D009388:Neostigmine; D009966:Orphenadrine; D006220:Haloperidol; D004298:Dopamine